Holen Sie sich die Stockscreener-App
1.355
3.90%
-0.055
Handel nachbörslich:
1.36
0.005
+0.37%
Schlusskurs vom Vortag:
$1.41
Offen:
$1.422
24-Stunden-Volumen:
4.65M
Relative Volume:
0.76
Marktkapitalisierung:
$420.71M
Einnahmen:
$160.01M
Nettoeinkommen (Verlust:
$-546.38M
KGV:
-0.7384
EPS:
-1.835
Netto-Cashflow:
$-118.92M
1W Leistung:
-12.58%
1M Leistung:
+1.12%
6M Leistung:
-27.15%
1J Leistung:
+20.98%
1-Tages-Spanne:
$1.35
$1.4497
1-Wochen-Bereich:
$1.35
$1.76
52-Wochen-Spanne:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.355 | 437.79M | 160.01M | -546.38M | -118.92M | -1.835 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Pacific Biosciences of California launches PacBioPRISM tour finale in Japan to drive HiFi innovation - Traders Union
Pacific Biosciences of California, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-05-11 - Seeking Alpha
PacBio expects $165M-$175M 2026 revenue as SPRQ-Nx ships later this month - MSN
PacBio tumbles after narrowing full-year revenue guidance - MSN
PACB Maintained by Barclays -- Price Target Raised to $1.50 - GuruFocus
Long-read genome scan spots key variants in unexplained subfertility - Stock Titan
PacBio (PACB) Q1 2026 Earnings Call Transcript - AOL.com
Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives - Sahm
Pacific Biosciences of California, Inc. Q1 2026 Financial Results and SEC 10-Q Filing Highlights - Minichart
[10-Q] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Quarterly Earnings Report - Stock Titan
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1Q 2026: Revenue $37.18M, EPS ($0.03) — 10-Q Summary - TradingView
Pacific Biosciences stock (US6932471010): Flat Q1 revenue amid funding pressure in U.S. research sec - AD HOC NEWS
Pacific Biosciences (PACB) Shares Drop Following Q1 Revenue Miss - GuruFocus
Why PacBio (PACB) Shares Are Getting Obliterated Today - The Globe and Mail
Pacific Biosciences of California, Inc. (PACB) Stock Rises on Q1 2026 Earnings - Moomoo
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down - Yahoo Finance
PACB Q1 Deep Dive: Consumables Growth and Clinical Adoption Offset Instrument Weakness - The Globe and Mail
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Pacific Biosciences of California, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pacific Biosciences of California Q1 Earnings Call Highlights - TradingView
HiFi sequencing from Pacific Biosciences of California offers no GC bias and stronger accuracy - Traders Union
Pacific Biosciences Reports Q1 Revenues Of $37 Mln - RTTNews
Pacific Biosciences Q1 2026 slides: consumables hit record amid product launch - Investing.com Canada
Pacific Biosciences (PACB) Reports Record Consumable Revenue in Q1 2026 - GuruFocus
Earnings call transcript: Pacific Biosciences reports Q1 2026 earnings beat By Investing.com - Investing.com Canada
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Pacific Biosciences: Q1 Earnings Snapshot - marketscreener.com
PacBio Announces First Quarter 2026 Financial Results - The Manila Times
PacBio (NASDAQ:PACB) Misses Q1 CY2026 Sales Expectations - Yahoo Finance
PacBio (NASDAQ: PACB) trims Q1 2026 loss, sets $165M–$175M revenue outlook - Stock Titan
Pacific Biosciences of California, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
A 100,000-sample gene atlas deal lands as PacBio posts $276M cash - Stock Titan
Here's why you should add PacBio stock to your portfolio now - MSN
MSN Money - MSN
PacBio (PACB) Q1 earnings report preview: What to look for - MSN
PacBio (PACB) Q1 Earnings Report Preview: What To Look For - Barchart.com
Pacific Biosciences of California pushes whole genome sequencing to transform newborn care - Traders Union
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now? - Yahoo Finance
NGS-based RNA-seq Market Size Accelerating at 14.8% CAGR | By Key - openPR.com
AI powers deep genomics gains as Pacific Biosciences of California improves sequencing accuracy and reduces costs - Traders Union
PACB Technical Analysis | Trend, Signals & Chart Patterns | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
Pacific Biosciences of California (PACB) dips more than broader market: What you should know - MSN
Pacific Biosciences of California presents new AAV workflow to reduce partial snapback genomes - Traders Union
Pacific Biosciences of California (PACB) Projected to Post Quarterly Earnings on Thursday - MarketBeat
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):